Interleukin (IL)-23 has been identified as a main driver of inflammation in inflammatory bowel disease (IBD) and has been identified as a target for highly effective advanced therapies. While all agents in the anti-IL-23 class of monoclonal antibodies (mABs) neutralize IL-23 by binding the Fab fragment to the P19 domain, the differences in Fc fragment structure may impact potency and clinical efficacy. Fc structure differences have been shown to impact binding of different agents to CD64 positive myelocytes, a main source of IL-23 in active IBD. In this CME Outfitters WebCast, expert faculty will review the role of the IL-23/Th-17 pathway in the pathogenesis of IBD and utilize animated 3-D models to illustrate differences in agents in the anti-IL-23 class that may have potential therapeutic implications. Learners will be guided through an evaluation of the potential clinical implications of CD64 receptor binding by anti-IL-23 mAbs in IBD treatment, as well as the clinical evidence supporting the benefits of these IBD treatment features.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/visualizing-the-future-advances-in-il-23-targeted-therapies-in-the-treatment-of-ibd-2/
- Start Date: 2024-06-10 05:00:00
- End Date: 2024-06-10 05:00:00
- Credit Details: IPCE Credits: 1.5 hours
AAPA Category 1 Credit™️: 1.5 hours
AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours - MOC Credit Details: ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Janssen (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Gastroenterology, Internal Medicine